Sina Raissi, MD
Nephrology · Middlebury, CTNPI 1053311662
Payments from drug & device makers
Across 434 payments — averaging $2826.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$365K
- AstraZeneca$203K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$187K
- GSK$154K
- Bayer$77K
- Akebia Therapeutics Inc$63K
- plus $178K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 9 | $365,225 |
| AstraZeneca(2 entities) | 40 | $203,186 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $186,811 |
| GSK | 85 | $153,509 |
| Bayer | 17 | $77,193 |
| Akebia Therapeutics Inc | 110 | $63,038 |
| Astrazeneca UK Limited | 4 | $50,138 |
| Boehringer Ingelheim International GmbH | 20 | $39,383 |
| Dynavax Technologies Corporation | 38 | $32,625 |
| Baxter Healthcare | 6 | $25,966 |
| Boehringer Ingelheim | 11 | $22,920 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 5 | $2,716 |
| Boehringer Ingelheim Limited | 2 | $1,880 |
| Mallinckrodt Hospital Products Inc. | 13 | $401 |
| Aurinia Pharma U.S., Inc. | 11 | $263 |
| Amgen(2 entities) | 8 | $177 |
| Otsuka America Pharmaceutical, Inc. | 7 | $169 |
| OPKO Pharmaceuticals, LLC | 6 | $138 |
| Vifor Pharma, Inc. | 5 | $111 |
| Calliditas Therapeutics US Inc. | 4 | $87 |
| Lilly USA, LLC | 3 | $86 |
| Fresenius USA Marketing, Inc. | 5 | $81 |
| Daiichi Sankyo Inc. | 4 | $70 |
| Novartis | 2 | $55 |
| Travere Therapeutics, Inc. | 6 | $54 |
| Ascendis Pharma Endocrinology Inc | 2 | $54 |
| Ultragenyx Pharmaceutical Inc. | 2 | $50 |
| Novo Nordisk | 2 | $44 |
| Sanofi | 2 | $39 |
| Ardelyx, Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$1,226,512 in reported general payments places this provider in the 95th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Middlebury
- David RoerMiddlebury$8K
- Mira RhoMiddlebury$3K
- Robert AlpernNew Haven$4.9M
- Sharad SathyanBloomfield$2.8M
- Jeffrey TurnerNew Haven$1.3M
- Ari GellerBloomfield$526K
- Aldo PeixotoNew Haven$362K
- Richard FormicaNew Haven$264K
- Meghana GaikiBloomfield$254K
- Fredric FinkelsteinNew Haven$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.